{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:rintatolimod [INN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03746769: Phase 1/Phase 2 Interventional Recruiting Diabetes Mellitus, Type 1
(2019)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
USAN:NIVOBOTULINUMTOXINA [USAN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
USAN:LETIBOTULINUMTOXINA [USAN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
USAN:GALINPEPIMUT-S [USAN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03924999: Not Applicable Interventional Completed Lipedema
(2019)
Source URL:
Class:
MIXTURE
Status:
Investigational
Class:
MIXTURE
Fallntolol is a beta-adrenergic receptor antagonist. Falintolol does not produce any noteworthy side effects and is capable of being an effective beta-blocking agent in open-angle glaucoma therapy.
Status:
Investigational
Source:
NCT01960972: Not Applicable Interventional Completed Blood Pressure
(2014)
Source URL:
Class:
MIXTURE
Status:
Investigational
Class:
MIXTURE
Status:
Investigational
Source:
NCT04456985: Not Applicable Interventional Recruiting Delirium
(2020)
Source URL:
Class:
MIXTURE